Hedy Migden, MD
Internal Medicine · Loudonville, NYNPI 1568422483
Payments from drug & device makers
Across 247 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$667
- Lilly USA, LLC$448
- Novo Nordisk$443
- Otsuka America Pharmaceutical, Inc.$324
- Sumitomo Pharma America, Inc.$223
- Merck$202
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,349100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 37 | $667 |
| Lilly USA, LLC | 26 | $448 |
| Novo Nordisk | 24 | $443 |
| Otsuka America Pharmaceutical, Inc. | 15 | $324 |
| Sumitomo Pharma America, Inc. | 14 | $223 |
| Merck | 13 | $202 |
| Teva Pharmaceuticals USA, Inc. | 9 | $171 |
| Astellas Pharma US Inc | 9 | $163 |
| Amgen | 8 | $143 |
| Exact Sciences | 7 | $138 |
| Lundbeck LLC | 7 | $136 |
| AstraZeneca | 9 | $126 |
| Pfizer | 6 | $101 |
| Axsome Therapeutics, Inc. | 6 | $91 |
| Hologic Sales And Service, LLC | 3 | $86 |
| Abbott | 4 | $79 |
| GSK | 5 | $78 |
| Indivior Inc. | 4 | $77 |
| Johnson & Johnson | 4 | $65 |
| Sunovion Pharmaceuticals Inc. | 3 | $63 |
| Idorsia Pharmaceuticals US Inc | 4 | $60 |
| Boehringer Ingelheim | 4 | $56 |
| Dexcom, Inc. | 3 | $53 |
| IBSA Pharma Inc. | 3 | $39 |
| Collegium Pharmaceutical, Inc. | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $29 |
| Seqirus USA Inc | 2 | $29 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Sanofi Pasteur Inc. | 1 | $28 |
| Amarin Pharma, Inc. | 2 | $28 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 2 | $24 |
| Corium, LLC | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Orexo US, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$4,349 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 109 | $150,790 |
| OzempicSemaglutide | 58 | $102,416 |
| RybelsusSemaglutide | 35 | $84,596 |
| MounjaroTirzepatide | 62 | $83,803 |
| EliquisApixaban | 45 | $64,415 |
| ProliaDenosumab | 33 | $56,282 |
| TrulicityDulaglutide | 30 | $44,407 |
| MyrbetriqMirabegron | 34 | $42,719 |
| GemtesaVibegron | 39 | $31,710 |
| FarxigaDapagliflozin Propanediol | 21 | $30,779 |
| RexultiBrexpiprazole | 12 | $27,326 |
| JanuviaSitagliptin Phosphate | 17 | $25,160 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $22,778 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $12,600 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $11,266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $443 | $187,01293 claims |
| Boehringer IngelheimJardiance | $56 | $150,790109 claims |
| Lilly USA, LLCMounjaro, Trulicity | $448 | $128,21092 claims |
| PfizerEliquis | $101 | $64,41545 claims |
| AmgenProlia | $143 | $56,28233 claims |
| Astellas Pharma US IncMyrbetriq | $163 | $42,71934 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $78 | $40,37246 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $223 | $31,71039 claims |
| AstraZenecaFarxiga | $126 | $30,77921 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $324 | $27,32612 claims |
| MerckJanuvia | $202 | $25,16017 claims |
| AbbVieSynthroid | $667 | $6,78475 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Loudonville
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.